Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 50.66 0.44% 0.22
EGRX closed up 0.44 percent on Friday, November 16, 2018, on 65 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical EGRX trend table...

Date Alert Name Type % Chg
Nov 16 Multiple of Ten Bullish Other 0.00%
Nov 15 NR7 Range Contraction 0.44%
Nov 15 Multiple of Ten Bullish Other 0.44%
Nov 15 Inside Day Range Contraction 0.44%
Nov 14 Multiple of Ten Bearish Other 2.38%
Nov 13 Multiple of Ten Bullish Other 0.10%
Nov 12 Down 3 Days in a Row Weakness 0.34%
Nov 8 1,2,3 Retracement Bearish Bearish Swing Setup -4.76%
Nov 8 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.76%
Nov 7 1,2,3 Retracement Bearish Bearish Swing Setup -4.99%

Older signals for EGRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 85.66
52 Week Low 46.88
Average Volume 273,081
200-Day Moving Average 64.898
50-Day Moving Average 60.3716
20-Day Moving Average 52.8515
10-Day Moving Average 51.39
Average True Range 2.6648
ADX 38.82
+DI 14.4553
-DI 25.454
Chandelier Exit (Long, 3 ATRs ) 53.0056
Chandelier Exit (Short, 3 ATRs ) 54.8744
Upper Bollinger Band 59.1603
Lower Bollinger Band 46.5427
Percent B (%b) 0.33
BandWidth 23.873684
MACD Line -3.0164
MACD Signal Line -3.3054
MACD Histogram 0.2891
Fundamentals Value
Market Cap 768.46 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 8.50
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.38
Resistance 3 (R3) 53.33 52.38 52.92
Resistance 2 (R2) 52.38 51.69 52.40 52.77
Resistance 1 (R1) 51.52 51.26 51.95 51.57 52.62
Pivot Point 50.57 50.57 50.79 50.59 50.57
Support 1 (S1) 49.71 49.88 50.14 49.76 48.70
Support 2 (S2) 48.76 49.45 48.78 48.55
Support 3 (S3) 47.90 48.76 48.40
Support 4 (S4) 47.95